Results 11 to 20 of about 20,923 (159)

Empagliflozin

Reactions Weekly
The Formulary Management Expert Committee (FMEC) recommends that empagliflozin be reimbursed for the treatment of chronic kidney disease (CKD) in adult patients with or without type 2 diabetes mellitus (T2DM), provided certain conditions are met ...
CDA-AMC
core   +18 more sources

Association between Empagliflozin Use and Electrocardiographic Changes

Clinics and Practice, 2022
Empagliflozin, a sodium-glucose transporter 2 inhibitor, has been shown to bind to late sodium channels in mice cardiomyocytes. We sought to investigate the electrocardiographic (ECG) features associated with empagliflozin use in patients with diabetes ...
Daniel Antwi-Amoabeng, Sunil Sathappan, Bryce D. Beutler, Mark B. Ulanja, Munadel Awad, Nageshwara Gullapalli, Phillip Duncan, T. David Gbadebo   +7 more
doaj   +2 more sources

Options for empagliflozin in combination therapy in type 2 diabetes mellitus

International Journal of General Medicine, 2016
Kenneth S Hershon1,2 1North Shore Diabetes and Endocrine Associates, New Hyde Park, 2Department of Medicine, Hofstra Northwell School of Medicine, Hempstead, NY, USA Objective: To update clinicians with an overview of empagliflozin for the treatment of ...
Hershon KS
doaj   +1 more source

Dapagliflozin versus empagliflozin in patients with chronic kidney disease [PDF]

Frontiers in Pharmacology, 2023
Background and Aim: Dapagliflozin and empagliflozin have demonstrated favorable clinical outcomes among patients with chronic kidney disease (CKD). However, their comparative monetary value for improving outcomes in CKD patients is unestablished.
Hilmi Alnsasra, Hilmi Alnsasra, Gal Tsaban, Gal Tsaban, Adam Solomon, Fouad Khalil, Enis Aboalhasan, Abed N. Azab, Abed N. Azab, Joseph Azuri, Joseph Azuri, Ariel Hammerman, Ronen Arbel   +12 more
doaj   +2 more sources

Empagliflozin: a new strategy for nephroprotection in diabetes [PDF]

Сахарный диабет, 2017
Empagliflozin, an inhibitor of sodium–glucose symporter type 2 (SGLT2), is a new class of antidiabetic agents with numerous pleiotropic effects. The review summarises data on the influence of empagliflozin on the structural and functional changes ...
Anton Ivanovich Korbut, Vadim Valer'evich Klimontov   +1 more
doaj   +2 more sources

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

, 2021
BACKGROUND Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction ...
Jose R Gonzalez-Juanatey (13954803), David Sim (13954812), Faiez Zannad (446278), Hans-Peter Brunner-La Rocca (8456529), Cordula Zeller (5328068), Michele Senni (7646837), Martina Brueckmann (575145), James L Januzzi (12367970), Sergio V Perrone (13954806), Jindrich Spinar (293654), Waheed Jamal (9319046), Peter Carson (9319040), Dragos Vinereanu (4914772), Janet M Schnee (13954815), Sven Schnaidt (6688667), Subodh Verma (3398249), Stuart J Pocock (7756850), Stefano Taddei (414259), Carolyn Su Ping Lam (12642994), Naveed Sattar (8785), Michael Boehm (3234591), Javed Butler (174923), Vijay Chopra (9319052), Piotr Ponikowski (357519), Ileana L Pina (13954809), Milton Packer (6822146), Stephen J Nicholls (9319064), Iain Squire (7686011), Dong-Ju Choi (515270), Stefan D Anker (8306655), Juan Esteban Gomez-Mesa (12699049), Nadia Giannetti (9319058), Joao P Ferreira (13954800), Hiroyuki Tsutsui (181537), Jian Zhang (1682), Gerasimos Filippatos (5926139), Edimar Bocchi (5926664), Nikolaus Marx (385207), Eduardo Chuquiure-Valenzuela (9727651), Stefan Janssens (390984), Bela Merkely (545484)   +40 more
core   +8 more sources

Empagliflozin Induces White Adipocyte Browning and Modulates Mitochondrial Dynamics in KK Cg-Ay/J Mice and Mouse Adipocytes

Frontiers in Physiology, 2021
Background: White adipose tissue (WAT) browning is a promising target for obesity prevention and treatment. Empagliflozin has emerged as an agent with weight-loss potential in clinical and in vivo studies, but the mechanisms underlying its effect are not
Linxin Xu, Linxin Xu, Chaofei Xu, Xiangyang Liu, Xiaoyu Li, Ting Li, Xiaochen Yu, Mei Xue, Jing Yang, Constantine E. Kosmas, Dimitrios Moris, Fabian Sanchis-Gomar, Naofumi Yoshida, Nathan A. Berger, Wilbert S. Aronow, Bei Sun, Liming Chen   +16 more
doaj   +1 more source

Empagliflozin: a potential anticancer drug

Discover Oncology, 2023
Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is a highly effective and well-tolerated antidiabetic drug. In addition to hypoglycemic effects, empagliflozin has many other effects, such as being hypotensive and cardioprotective.
Wenwen Wu, Yanyan Wang, Jun Xie, Shaohua Fan   +3 more
doaj   +1 more source

Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure [PDF]

, 2021
International audienceBackground: Mineralocorticoid receptor antagonists (MRAs) and sodium glucose co-transporter 2 inhibitors favorably influence the clinical course of patients with heart failure and reduced ejection fraction.Objectives: This study ...
Jamal, Waheed, Steubl, Dominik, Anker, Stefan D, Zannad, Faiez, Pocock, Stuart J, Filippatos, Gerasimos, Brueckmann, Martina, Anker, Stefan, D, Pocock, Stuart, J, Schueler, Elke, Anker, Stefan,, Packer, Milton, Pocock, Stuart,, Butler, Javed, Ferreira, João Pedro   +14 more
core   +1 more source

Empagliflozin improves primary haemodynamic parameters and attenuates the development of atherosclerosis in high fat diet fed APOE knockout mice [PDF]

, 2019
The effects of long-term treatment with empagliflozin on biochemical and immunohistochemical markers related to atherosclerosis and atherosclerosis development in the aorta of apolipoprotein E knockout [Apo-E (−/−)] mice were evaluated in this study ...
Patel, Vanlata H., Randeva, Harpal S., Randeva, Manpal S., Kaltsas, Gregory, Kostakis, Ioannis D., Dimitriadis, Georgios K., Nikiteas, Nikolaos, Kassi, Eva, Nasiri-Ansari, Narjes, Agrogiannis, Georgios, Papavassiliou, Athanasios G.   +10 more
core   +1 more source